7 May 2021 - A drug to treat a rare muscle disease which affects some 20 children in the Netherlands a year should not be included in the basic insurance package unless the price is halved, government advisory group Zorginstituut Nederland has said in new recommendations.
In addition, pharmaceutical company Novartis should also agree to payment on the basis of the actual results, the institute said.